Clinical Trial Update: Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy monitoring by ctDNA in HER2-negative metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Institut Curie | Conditions: HER2-negative Metastatic Breast Cancer | Phase 2 | Status: TERMINATED